• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童艰难梭菌感染(综述)

Clostridium difficile infection in pediatric patients (Review).

作者信息

Dop Dalia, Marcu Iulia Rahela, Padureanu Vlad, Caragea Daniel Cosmin, Padureanu Rodica, Niculescu Stefan-Adrian, Niculescu Carmen Elena

机构信息

Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Department of Physical and Rehabilitation Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

出版信息

Biomed Rep. 2023 Dec 8;20(2):18. doi: 10.3892/br.2023.1706. eCollection 2024 Feb.

DOI:10.3892/br.2023.1706
PMID:38169799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10758920/
Abstract

infection (CDI) is the most common cause of healthcare-associated diarrhea and among adults, the worldwide incidence rate of the infection is increasing. There is a small amount of data in the literature for pediatric patients, but most indicate an increasing trend. is a constituent of the normal microbiota; however, under specific conditions that cause a disruption of the normal bacterial flora, colonization of and the released toxins that cause inflammation and mucosal damage occurs. Risk factors for CDI at any age include hospitalization, exposure to antibiotics, administration of proton pump inhibitors, invasive mechanical ventilation, immunosuppression and presence of associated comorbidities. Clinical manifestations range from asymptomatic colonization to fulminant disease characterized by toxic megacolon, intestinal perforation and, rarely, death. The aim of the present review was to outline the features of CDI in pediatric patients.

摘要

艰难梭菌感染(CDI)是医疗保健相关腹泻的最常见原因,在成年人中,该感染的全球发病率正在上升。文献中关于儿科患者的数据较少,但大多数表明呈上升趋势。艰难梭菌是正常微生物群的组成部分;然而,在导致正常细菌菌群破坏的特定条件下,艰难梭菌会定植并释放毒素,从而引起炎症和粘膜损伤。任何年龄段CDI的危险因素包括住院、接触抗生素、使用质子泵抑制剂、有创机械通气、免疫抑制以及存在相关合并症。临床表现从无症状定植到以中毒性巨结肠、肠穿孔以及罕见的死亡为特征的暴发性疾病不等。本综述的目的是概述儿科患者CDI的特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/10758920/3004e58d76b8/br-20-02-01706-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/10758920/3004e58d76b8/br-20-02-01706-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0c8/10758920/3004e58d76b8/br-20-02-01706-g00.jpg

相似文献

1
Clostridium difficile infection in pediatric patients (Review).儿童艰难梭菌感染(综述)
Biomed Rep. 2023 Dec 8;20(2):18. doi: 10.3892/br.2023.1706. eCollection 2024 Feb.
2
- From Colonization to Infection.- 从定植到感染。
Front Microbiol. 2018 Apr 10;9:646. doi: 10.3389/fmicb.2018.00646. eCollection 2018.
3
Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.兴衰:肠道微生物群对医院暴露和艰难梭菌定植或感染的反应动态。
Microbiome. 2016 Mar 14;4:12. doi: 10.1186/s40168-016-0156-3.
4
infection: an update.感染:最新进展。
Infez Med. 2024 Sep 1;32(3):280-291. doi: 10.53854/liim-3203-3. eCollection 2024.
5
Pediatric oncology and stem cell transplant patients with healthcare-associated Clostridium difficile infection were already colonized on admission.儿科肿瘤和干细胞移植患者在入院时就已经被与医疗保健相关的艰难梭菌感染定植。
Pediatr Blood Cancer. 2019 May;66(5):e27604. doi: 10.1002/pbc.27604. Epub 2019 Jan 21.
6
Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.分子检测时代艰难梭菌感染的过度诊断
JAMA Intern Med. 2015 Nov;175(11):1792-801. doi: 10.1001/jamainternmed.2015.4114.
7
Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.艰难梭菌感染与质子泵抑制剂在成人和儿科患者中的关联程度和方向:系统评价和荟萃分析。
J Gastroenterol. 2018 Jan;53(1):84-94. doi: 10.1007/s00535-017-1369-3. Epub 2017 Jul 25.
8
Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.老年人艰难梭菌性腹泻:当前问题与管理选项
Drugs Aging. 2015 Aug;32(8):639-47. doi: 10.1007/s40266-015-0289-2.
9
Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.接受高风险抗生素治疗的患者中,使用质子泵抑制剂与不使用质子泵抑制剂的艰难梭菌感染发生率。
J Hosp Infect. 2016 Feb;92(2):173-7. doi: 10.1016/j.jhin.2015.10.009. Epub 2015 Nov 2.
10
Association of healthcare exposure with acquisition of different Clostridium difficile strain types in patients with recurrent infection or colonization after clinical resolution of initial infection.医疗机构暴露与初始感染临床治愈后复发感染或定植患者获得不同艰难梭菌菌株类型的相关性。
J Hosp Infect. 2016 Feb;92(2):167-72. doi: 10.1016/j.jhin.2015.11.009. Epub 2015 Nov 26.

本文引用的文献

1
Updates and Opinions in Diagnosis and Treatment of in Pediatrics.儿科诊断与治疗的最新进展及观点
Curr Treat Options Pediatr. 2021;7(4):203-216. doi: 10.1007/s40746-021-00232-9. Epub 2021 Dec 4.
2
Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy.儿童艰难梭菌感染:流行病学、诊断、治疗的最新进展。
Pediatrics. 2023 Sep 1;152(3). doi: 10.1542/peds.2023-062307.
3
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
接受抗菌治疗的艰难梭菌感染患儿中贝洛妥珠单抗的双盲、安慰剂对照研究(MODIFY III)。
J Pediatric Infect Dis Soc. 2023 Jun 30;12(6):334-341. doi: 10.1093/jpids/piad031.
4
Clostridioides difficile infection in infants: a case report and literature review.婴儿艰难梭菌感染:一例病例报告及文献综述
Gut Pathog. 2023 Jun 29;15(1):31. doi: 10.1186/s13099-023-00552-1.
5
Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3.MGB-BP-3 的作用机制和作用谱的深入研究
ACS Infect Dis. 2022 Dec 9;8(12):2552-2563. doi: 10.1021/acsinfecdis.2c00445. Epub 2022 Nov 29.
6
Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013 to 2019.艰难梭菌感染住院儿科患者:2013 年至 2019 年流行病学、检测和治疗的比较。
J Pediatr. 2023 Jan;252:111-116.e1. doi: 10.1016/j.jpeds.2022.08.030. Epub 2022 Aug 24.
7
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.伊贝扎泊司他治疗艰难梭菌感染成人患者的疗效、安全性、药代动力学及微生物组变化:一项2a期多中心临床试验
Clin Infect Dis. 2022 Sep 30;75(7):1164-1170. doi: 10.1093/cid/ciac096.
8
Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature.儿童相关的艰难梭菌感染:文献复习。
J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S22-S26. doi: 10.1093/jpids/piab064.
9
Oral Vancomycin as Secondary Prophylaxis for Infection.口服万古霉素作为 感染的二级预防。
Pediatrics. 2021 Aug;148(2). doi: 10.1542/peds.2020-031807.
10
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.美国传染病学会 (IDSA) 和美国医疗保健流行病学学会 (SHEA) 的临床实践指南:2021 年关于成人艰难梭菌感染管理的重点更新指南。
Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549.